Novartis uses Homology's AMEnDR gene editing platform to develop ophthalmic, blood disorder therapeutics; partnership cancelled
Executive Summary
Novartis AG licensed exclusive worldwide rights to Homology Medicines Inc.'s AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) gene editing technology platform to develop therapeutics for a blood disease and select ophthalmic targets.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice